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Abstract
The WNT/B-catenin (CTNNB1) pathway is commonly ac-
tivated in the carcinogenic process. Cross-talks between
the WNT and cyclooxygenase-2 (COX-2 or PTGS2)/pros-
taglandin pathways have been suggested. The rela-
tionship between B-catenin activation and microsatellite
instability (MSI) in colorectal cancer has been contro-
versial. The CpG island methylator phenotype (CIMP
or CIMP-high) with widespread promoter methylation
is a distinct epigenetic phenotype in colorectal cancer,
which is associated with MSI-high. However, no study
has examined the relationship between B-catenin ac-
tivation and CIMP status. Using 832 population-based
colorectal cancer specimens, we assessed B-catenin lo-
calization by immunohistochemistry. We quantified DNA
methylation ineightCIMP-specificpromoters [CACNA1G,
CDKN2A (p16),CRABP1, IGF2,MLH1,NEUROG1,RUNX3,
and SOCS1] by real-time polymerase chain reaction
(MethyLight). MSI-high, CIMP-high, and BRAF mutation
were associated inversely with cytoplasmic and nuclear
B-catenin expressions (i.e., B-catenin activation) and
associated positively with membrane expression. The
inverse relation between B-catenin activation and CIMP
was independent of MSI. COX-2 overexpression corre-
lated with cytoplasmic B-catenin expression (even after
tumors were stratified by CIMP status), but did not
correlate significantly with nuclear or membrane ex-
pression. In conclusion, B-catenin activation is inversely
associated with CIMP-high independent of MSI status.
Cytoplasmic B-catenin is associated with COX-2 over-
expression, supporting the role of cytoplasmic B-catenin
in stabilizing PTGS2 (COX-2) mRNA.
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Introduction
Transcriptional inactivation by cytosine methylation at pro-
moter CpG islands of tumor-suppressor genes is an impor-
tant mechanism in human carcinogenesis [1]. A number of
tumor-suppressor genes have been shown to be silenced by
promoter methylation in colorectal cancers [1]. In fact, a subset
of colorectal cancers has been shown to exhibit promoter
methylation in multiple genes, which is referred to as the
CpG island methylator phenotype (CIMP) [2]. CIMP-positive
colorectal tumors have a distinct clinical, pathological, and
molecular profile, such as associations with proximal tumor
location, female gender, poor differentiation, microsatellite
instability (MSI), and high BRAF and low TP53 mutation rates
[3–6]. Promoter CpG island methylation has been shown to
occur early in colorectal carcinogenesis [7].
WNT genes and products (derived from ‘‘Wingless’’ and
‘‘INT’’) constitute the WNT signaling pathway, which controls
virtually every developmental decision making [8]. The cen-
tral player in the WNT pathway is b-catenin [CTNNB1, the
Human Genome Organization–approved official gene sym-
bol; catenin (cadherin-associated protein), b1], whose stabil-
ity is regulated by APC complex [8]. When WNT receptors
are inactive, b-catenin localizes with the membrane protein
E-cadherin (CDH1), and kinases in the APC complex phos-
phorylate cytoplasmic b-catenin for its rapid degradation.
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When WNT receptors are activated, kinases in the APC
complex are inhibited, leading to accumulation of cytoplasmic
b-catenin and its translocation to the nucleus, where it facili-
tates the transcription of various target genes [8]. Other path-
ways implicated in cross-talks with the WNT pathway include
the transforming growth factor-b (TGF-b) pathway [9] and
the cyclooxygenase-2 [COX-2 or PTGS2 (prostaglandin–
endoperoxide synthase 2)]/prostaglandin pathway [10–13].
Activation of WNT/b-catenin signaling has been implicated in
various human malignancies, and both APC and CTNNB1
have been shown to be targets of genetic/epigenetic alter-
ations in colorectal cancer [14–20]. There are conflicting data
regarding correlations of b-catenin activation with MSI status
in colorectal cancer [19,21–27]. Moreover, no study has com-
prehensively examined the relationship between b-catenin
and CIMP in colorectal cancer. Molecular correlates with
b-catenin activation are important in understanding car-
cinogenic mechanisms in various molecular subtypes of
colorectal cancer.
In this study, using quantitative DNA methylation analysis
(MethyLight technology) and a large number of population-
based colorectal cancer samples, we examined b-catenin
expression in relation to various clinicopathological and mo-
lecular features, especially COX-2 expression and combined
MSI and CIMP statuses. We have found an inverse correla-
tion between b-catenin activation and CIMP, and a positive
correlation between cytoplasmic b-catenin expression and
COX-2 overexpression. Our results indicate that one should
examine CIMP status when analyzing WNT/b-catenin path-
way activation in relation to clinical and/or other molecular
variables because CIMP status reflects global epigenomic
status in tumor cells and may be a confounding factor.
Materials and Methods
Study Group
We used the databases of two large prospective cohort
studies: the Nurses’ Health Study (n = 121,700 women
followed since 1976) [28] and the Health Professional
Follow-up Study (n = 51,500 men followed since 1986)
[29]. Informed consent was obtained from all participants
before inclusion into cohorts. We excluded from analyses all
cohort participants with cancer (except for nonmelanoma
skin cancer) at the time of study entry. A subset of cohort
participants developed colorectal cancers during prospec-
tive follow-up. Thus, these colorectal cancers represented
population-based relatively unbiased samples (compared to
retrospective or single hospital–based samples). Previous
studies on Nurses’ Health Study and Health Professional
Follow-up Study have described baseline characteristics of
cohort participants and incident colorectal cancer cases, and
they have confirmed that our colorectal cancer cases were
representative as a population-based sample [28,29]. Follow-
up of these cohorts is ongoing, and survival data have not
yet been made available. We collected paraffin-embedded
tissue blocks from hospitals where cohort participants with
colorectal cancers had undergone resections of primary
tumors. We excluded cases if adequate paraffin-embedded
tumor tissue was not available at the time of the study. As
a result, 832 colorectal cancer cases (365 from men’s cohort
and 467 from women’s cohort) were included. Among our
cohort studies, there was no significant difference in demo-
graphic features between cases with available tissue and
those without available tissue [30]. Many of the cases have
been previously characterized for CIMP, MSI, KRAS, and
BRAF statuses [5,31]. However, no tumor has been exam-
ined for b-catenin expression in our previous studies. Tissue
collection and analyses were approved by the Institutional
Review Boards of the Dana-Farber Cancer Institute and the
Brigham and Women’s Hospital.
Histopathological Evaluation
Hematoxylin and eosin–stained tissue sections were
examined under a light microscope by one of the investiga-
tors (S.O.) blinded from clinical and other laboratory data.
Tumors were classified into well/moderately differentiated
(< 50% solid areas) and poorly differentiated tumors (z 50%
solid areas). In addition, the extent and the type of mucinous
component in each tumor were evaluated, and tumors were
classified into five categories: 1) tumors with no mucinous or
signet ring cell component (nonmucinous tumors); 2) tumors
with 1% to 49%mucinous component but no signet ring cells;
3) tumors with z 50% mucinous component but no signet
ring cells; 4) tumors with 1% to 49% signet ring cell compo-
nent; and 5) tumors with z 50% signet ring cell component.
Genomic DNA Extraction and Whole Genome
Amplification (WGA)
Genomic DNA was extracted from dissected tumor tissue
sections using QIAmp DNA Mini Kit (Qiagen, Valencia, CA),
as previously described [32]. Normal DNAwas obtained from
colonic tissues at resection margins. WGA of genomic DNA
was performed by polymerase chain reaction (PCR) using
random 15-mer primers [32] for subsequent MSI analysis
and KRAS and BRAF sequencing. Previous studies by us
and others have shown that WGA did not significantly affect
KRAS mutation detection or microsatellite analysis [32,33].
MSI Analysis and Loss of Heterozygosity (LOH) for APC
Methods used to analyze MSI status and mutation in
TGFBR2 (the TGF-b receptor type 2 gene) have been pre-
viously described [34,35]. In addition to the recommended
MSI panel consisting of D2S123, D5S346, D17S250, BAT25,
and BAT26 [36], we also used BAT40, D18S55, D18S56,
D18S67, and D18S487 (i.e., a 10-marker panel) [34]. A ‘‘high
degree of MSI’’ (MSI-high) was defined as the presence
of instability in z 30% of markers. A low degree of MSI (MSI-
low) was defined as the presence of instability in < 30%
of markers, and ‘‘microsatellite stable’’ (MSS) tumors were
defined as tumors without an unstable marker. LOH positiv-
ity at the APC (D5S346) locus was defined as a z 40%
reduction in one of two allele peaks in two duplicated runs
in tumor DNA relative to normal DNA.
570 B-Catenin, COX-2 and CIMP in Colorectal Cancer Kawasaki et al.
Neoplasia . Vol. 9, No. 7, 2007
Sequencing of KRAS and BRAF
Methods of PCR and sequencing targeted for KRAS
codons 12 and 13 and BRAF codon 600 have been previously
described [32,37]. Pyrosequecing was performed using the
PSQ96 HS System (Biotage AB and Biosystems, Uppsala,
Sweden), according to the manufacturer’s instructions.
Real-Time PCR (MethyLight) for Quantitative DNA
Methylation Analysis
Sodium bisulfite treatment on genomic DNA was per-
formed as previously described [38]. Real-time PCR to
measure DNA methylation (MethyLight) was performed
as previously described [39,40]. Using ABI 7300 (Applied
Biosystems, Foster City, CA) for quantitative real-time PCR,
we used eight CIMP-specific promoters [CACNA1G (cal-
cium channel, voltage-dependent, T type a-1G subunit);
CDKN2A (cyclin-dependent kinase inhibitor 2A, p16/INK4A);
CRABP1 (cellular retinoic acid binding protein 1); IGF2
(insulin-like growth factor 2); MLH1; NEUROG1 (neurogenin
1); RUNX3 (runt-related transcription factor); and SOCS1
(suppressor of cytokine signaling 1)] [5,6] as a CIMP diag-
nostic panel [31].COL2A1 (the collagen 2A1 gene) was used
to normalize for the amount of input bisulfite-converted DNA
[38,40]. Primers and probes had been previously described
[6]. The percentage of methylated reference (PMR; i.e.,
degree of methylation) at a specific locus was calculated
by dividing theGENE:COL2A1 ratio of template amounts in a
sample by the GENE:COL2A1 ratio of template amounts in
SssI-treated human genomic DNA (presumably fully meth-
ylated) and multiplying this value by 100 [39]. A PMR cutoff
value of 4 was based on previously validated data [5,38]. We
set a PMR cutoff value of 6 for CRABP1 and IGF2 based on
PMR distribution. The precision and performance character-
istics of bisulfite conversion and subsequent MethyLight
assays have been previously evaluated, and such assays
have been validated [38].
CIMP-high was defined as the presence of z 6 of 8 meth-
ylated promoters; CIMP-low was defined as the presence of
1 to 5 of 8 methylated promoters; and CIMP-0 was defined as
the absence (0 of 8) of methylated promoters, according to
previously established criteria [31].
Tissue Microarrays (TMAs) and Immunohistochemistry
for COX-2 and p53
TMAs were constructed as previously described [41],
using Automated Arrayer (Beecher Instruments, Sun Prairie,
WI). We examined two to four tumor tissue cores for each
marker. A previous validation study has shown that ex-
amining two TMA cores can yield results comparable to
those when examining whole tissue sections in > 95% of
cases [42]. We examined whole tissue sections for cases in
which no tissue block was available for TMA construction or
for cases in which results were equivocal in TMAs.
Immunohistochemistry for p53 and COX-2 was per-
formed as previously described [30,43]. p53 positivity was
defined as z 50% of tumor cells with unequivocal strong
nuclear staining. COX-2 overexpression was recorded as
positive, weak, or negative compared to normal colonic
mucosa. Appropriate positive and negative controls were in-
cluded in each run of immunohistochemistry. All immuno-
histochemically stained slides were interpreted by one of
the investigators (S.O.) blinded from any other clinical and
laboratory data. A random sample of 108 cases was ex-
amined for COX-2 expression by a second observer (R.D.),
and the concordance between the two observers was 0.92
(j coefficient = 0.62) [30].
Immunohistochemistry for -Catenin
For b-catenin immunohistochemistry, antigen retrieval
was performed; deparaffinized tissue sections in citrate
buffer (BioGenex, San Ramon, CA) were treated with micro-
wave in a pressure cooker for 15 minutes. Tissue sections
were incubated with 3% H2O2 (15 minutes) to block endoge-
nous peroxidase, with 10% normal goat serum (Vector
Laboratories, Burlingame, CA) in phosphate-buffered saline
(10 minutes), and with serum-free protein block (10 minutes;
DAKO, Carpinteria, CA). Primary antibody against b-catenin
(clone 14; 1:400 dilution; BD Transduction Laboratories,
Franklin Lakes, NJ) was applied for 1 hour at room temper-
ature. Secondary antibody (20 minutes; BioGenex) and then
streptavidin peroxidase conjugate (20 minutes; BioGenex)
were applied. Sections were visualized by diaminobenzidine
(2 minutes) and methyl green counterstain. Normal colonic
epithelial cells served as internal positive controls with
membrane staining (Figure 1). Cytoplasmic, nuclear, and
membrane expressions were recorded separately as either
no expression, weak expression, or moderate/strong expres-
sion. Positivity in each compartment (cytoplasm, nucleus, or
membrane) was defined as moderate/strong expression in
that compartment. We also calculated b-catenin activation
score as the sum of nuclear score (+2 = positive expression;
+1 =weak expression; 0 = no expression), cytoplasmic score
(+2 = positive expression; +1 = weak expression; 0 = no
expression), and membrane score (0 = positive membrane
expression; +1 = negative membrane expression), as previ-
ously described by Jass et al. [26]. Appropriate positive and
negative controls were included in each run of immunohis-
tochemistry. All immunohistochemically stained slides were
interpreted by one of the investigators (K.N.) blinded from
any other clinical and laboratory data. A second observer
(S.O.) examined 402 cases, and j coefficients for agreement
in these 402 cases were as follows: 0.52 for cytoplasmic
positivity, 0.63 for nuclear positivity, 0.57 for membrane
positivity, and 0.65 for b-catenin scores z 4 (all P < .0001),
indicating overall moderate to substantial agreement.
Statistical Analysis
In statistical analysis, chi-square test (or Fisher’s exact
test when the number in any category was < 10) was
performed for categorical data, and j coefficients were
calculated to determine the degree of agreement between
two observers, using SAS program, Version 9.1 (SAS Insti-
tute, Cary, NC). All P values were two-sided, and statistical
significance was set at P V .05.
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Results
-Catenin Expression in Colorectal Cancer
We examined b-catenin expression in 832 colorectal
cancers by immunohistochemistry (Figure 1). Among the
832 tumors, 336 (40%) showed cytoplasmic positivity, 381
(46%) showed nuclear positivity, and 328 (39%) showed
membrane positivity. Cytoplasmic and nuclear expressions
were correlated positively with each other (P < .0001) and
correlated inversely with membrane expression (P < .0001)
(detailed data not shown).
Table 1 shows the frequencies of b-catenin expression in
colorectal cancers according to clinical or pathological fea-
tures. Carcinomas with mucinous component, right-sided
tumors, and poorly differentiated tumors generally showed
lower frequencies of cytoplasmic/nuclear b-catenin expres-
sion and higher frequencies of membrane expression, com-
pared to nonmucinous tumors, left-sided tumors, and well/
moderately differentiated tumors, respectively.
MSI-High, CIMP-High, and BRAF Mutation Are Inversely
Associated with -Catenin Activation
Using MethyLight technology, we quantified DNA meth-
ylation in a CIMP-specific marker panel of eight promoters
(CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1,
RUNX3, and SOCS1) [5,6,31]. Among 789 tumors with
CIMP status determined, there were 108 (14%) CIMP-high
tumors (z 6 of 8 methylated promoters), 301 (38%) CIMP-
low tumors (1 to 5 of 8 methylated promoters), and 380 (48%)
CIMP-0 tumors (0 of 8 methylated promoters). CIMP-high,
MSI-high, and BRAF-mutated tumors showed significantly
lower frequencies of cytoplasmic and nuclear expressions
and higher frequencies of membrane b-catenin expression
(Table 2).
We also calculated b-catenin activation scores based on
the methods of Jass et al. [26]. Briefly, b-catenin score was
the sum (0–5) of nuclear (0, +1, or +2), cytoplasmic (0, +1, or
+2), and membrane (0 = positive membrane expression;
+1 = negative membrane expression) scores, and was
considered to reflect the degree of b-catenin activation [26].
CIMP-high, MSI-high, and BRAF-mutated tumors showed
low frequencies of b-catenin scores z 4, indicating low fre-
quencies of b-catenin activation in these tumors (Table 3).
Because of the possible cross-talk between the WNTand
TGF-b pathways, we examined the relationship between b-
catenin expression and TGFBR2 mutation (mononucleotide
repeat) in MSI-high tumors; however, there was no signifi-
cant correlation (data not shown).
The Inverse Relation between -Catenin Activation and
CIMP-High Is Independent of MSI or BRAF Status
To examine the effect of CIMP (or MSI) on b-catenin
expression independent of MSI status (or CIMP status), we
classified tumors into four subtypes according to combined
Figure 1. -Catenin expression in colorectal cancer. (A) Normal colorectal epithelial cells with membrane expression (arrows). (B) Colorectal cancer with
membrane expression (arrow). (C) Colorectal cancer with strong cytoplasmic expression (empty arrows). (D) Colorectal cancer with nuclear expression (empty
arrowheads).
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MSI and CIMP statuses (Figure 2). The inverse relation
between nuclear/cytoplasmic b-catenin (or high b-catenin
score) and CIMP-high, as well as the positive correlation
between membrane b-catenin and CIMP-high, persisted
even after tumors had been stratified by MSI status. How-
ever, the relationship between MSI and b-catenin expression
did not persist after tumors had been stratified by CIMP
status (Figure 2). These data implied that the relationship
between b-catenin and CIMP was independent of MSI status
and that the relationship between b-catenin and MSI was
mediated by CIMP.
CIMP and BRAF are tightly correlated, and BRAF and
KRAS mutations are inversely correlated. To examine the
effect of CIMP (or BRAF mutation) on b-catenin expression
independent of BRAF status (or CIMP status), we stratified
tumors according to CIMP, KRAS, and BRAF statuses
(Figure 3). The relationship between CIMP and b-catenin
appeared to be independent of BRAF mutation, whereas the
relationship between BRAF mutation and b-catenin was not
present in CIMP-high tumors. CIMP-low/CIMP-0 tumors with
BRAF mutation appeared to show b-catenin expression
profiles similar to those of CIMP-high tumors. This is perhaps
because BRAF-mutated CIMP-low/CIMP-0 tumors were, by
themselves, uncommon (only n = 31) and might contain rare
CIMP-high tumors misdiagnosed as CIMP-low tumors (false
negatives). However, the possible effect of BRAF mutation
Table 1. Frequency of b-Catenin Expression in Colorectal Cancer.
Total n Cytoplasmic Nuclear Membrane
(+) [n (%)] P (+) [n (%)] P (+) [n (%)] P
All cases 832 336 (40) 381 (46) 328 (39)
Men 365 150 (41) 168 (46) 123 (34) Referent
Women 467 186 (40) 213 (46) 205 (44) .003
Differentiation
Well/moderate 743 311 (42) Referent 349 (47) 283 (38) Referent
Poor 65 18 (28) .03 23 (35) 33 (51) .04
Mucinous/signet ring cell features
Nonmucinous carcinoma 553 244 (44) Referent 283 (51) Referent 195 (35) Referent
Carcinoma with mucinous component (no signet ring cell)
1–49% mucinous 169 56 (33) 58 (34) .0001 76 (45) .02
z 50% mucinous 62 19 (31) .04 24 (39) 34 (55) .003
Carcinoma with signet ring cell component
1–49% signet ring cells 38 13 (34) 11 (29) .008 20 (53) .03
z 50% signet ring cells 10 4 (40) 5 (50) 3 (30)
Location
Right 226 66 (29) Referent 70 (31) Referent 138 (61) Referent
Left (excluding rectum) 164 89 (54) < .0001 99 (60) < .0001 53 (39) < .0001
Rectum 96 55 (57) < .0001 55 (57) < .0001 28 (29) < .0001
Only significant P values are described.
Table 2. Frequency of b-Catenin Expression in Colorectal Cancer with Various Molecular Features.
Molecular Feature Total n Cytoplasmic Nuclear Membrane
(+) [n (%)] P (+) [n (%)] P (+) [n (%)] P
MSI status
MSI-high 108 21 (19) < .0001 28 (26) < .0001 67 (62) < .0001
MSI-low 64 26 (41) 31 (48) 26 (41)
MSS 629 263 (45) Referent 307 (49) Referent 223 (35) Referent
CIMP status
CIMP-high 108 14 (13) < .0001 20 (19) < .0001 37 (74) < .0001
CIMP-low 301 117 (39) 129 (43) 58 (48)
CIMP-0 380 187 (49) Referent 218 (57) Referent 42 (33) Referent
KRAS mutation
(+) 290 128 (44) 134 (49) 98 (74) < .0001
() 500 196 (39) 225 (45) 215 (43) Referent
BRAF mutation
(+) 99 16 (16) < .0001 23 (23) < .0001 67 (68) < .0001
() 691 308 (45) Referent 336 (49) Referent 246 (36) Referent
p53 expression
(+) 362 162 (45) .02 192 (53) .0003 119 (33) .0006
() 463 171 (37) Referent 187 (40) Referent 207 (45) Referent
COX-2 overexpression
Strong (+) 55 32 (58) .001 31 (56) 19 (35)
(+) 349 145 (42) 155 (44) 142 (41)
() 90 28 (31) Referent 36 (40) 37 (41)
D5S346 (APC) LOH
(+) 136 64 (47) 75 (55) 40 (29)
() 262 118 (45) 123 (47) 98 (37)
Only significant P values are described.
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on b-catenin expression in CIMP-low/CIMP-0 tumors could
not be completely excluded.
COX-2 Overexpression Is Significantly Correlated
with Cytoplasmic -Catenin Expression, Even
after Stratification By CIMP Status
Interestingly, compared to COX-2–negative tumors, COX-
2–strong positive tumors showed a significantly higher fre-
quency of cytoplasmic b-catenin expression (58% vs 31%, P =
.001), but no significant relationship was present between
COX-2 and nuclear (or membrane) b-catenin expression
(Table 2). COX-2–strong positive tumors showed a signifi-
cantly higher frequency of b-catenin scoresz 4 than did COX-
2–negative tumors (58% vs 33%, P = .003) (Table 3).
COX-2 overexpression was inversely associated with
CIMP in our previous analysis [41]. To examine the effect
of COX-2 (or CIMP) on b-catenin expression independent
of CIMP status (or COX-2 status), we classified tumors ac-
cording to combined CIMP and COX-2 statuses (Figure 4).
It appeared that COX-2 overexpression correlated with cy-
toplasmic b-catenin expression after stratification by CIMP
status and that CIMP-high inversely correlated with cyto-
plasmic b-catenin expression and high b-catenin score inde-
pendent of COX-2 status. Nuclear or membrane b-catenin
expression did not correlate with COX-2 expression after
stratification by CIMP status (data not shown).
Because we have previously shown the synergistic effect
of COX-2 and p53 expressions (on CIMP and MSI) [41], we
examined whether the effect of COX-2 on cytoplasmic
b-catenin was modified by p53 status. As shown in Figure 5,
there appeared to be a synergistic effect of COX-2 and p53 on
cytoplasmic b-catenin expression, and the effect of COX-2 on
Table 3. b-Catenin Activation Score and Various Molecular Features in
Colorectal Cancer.
Molecular Feature Total n b-Catenin Score* z 2 b-Catenin Score* z 4
n (%) P n (%) P
All cases 832 559 (67) 352 (42)
MSI status
MSI-high 108 48 (44) < .0001 20 (19) < .0001
MSI-low 64 45 (70) 29 (45)
MSS 629 446 (71) Referent 292 (46) Referent
CIMP status
CIMP-high 108 41 (38) < .0001 13 (12) < .0001
CIMP-low 301 193 (64) 118 (39)
CIMP-0 380 297 (78) Referent 207 (54) Referent
KRAS mutation
(+) 290 202 (70) 131 (45)
() 500 328 (66) 203 (41)
BRAF mutation
(+) 99 44 (44) < .0001 13 (13) < .0001
() 691 486 (70) Referent 321 (46) Referent
p53 expression
(+) 362 264 (73) .002 179 (49) .0003
() 463 290 (63) Referent 171 (37) Referent
COX-2 overexpression
Strong (+) 55 43 (78) 32 (58) .003
(+) 349 237 (68) 144 (41)
() 90 61 (68) 30 (33) Referent
D5S346 (APC) LOH
(+) 136 102 (75) 71 (52)
() 262 173 (66) 117 (45)
Only significant P values are described.
*The b-catenin activation score is based on the criteria of Jass et al. [26].
Figure 3. Frequencies of -catenin expression and -catenin scores z 4 in
colorectal cancer stratified by CIMP, KRAS (K), and BRAF (B) statuses.
Figure 2. Frequencies of -catenin expression and -catenin scores z 4 in colorectal cancer stratified by MSI and CIMP statuses. Note that the relationship
between CIMP and -catenin is independent of MSI status.
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cytoplasmic b-catenin appeared to be substantial, whereas
there was some (but smaller) effect of p53.
Discussion
We conducted this study to examine molecular correlates
with b-catenin activation in colorectal cancer, using a large
number of samples and robust DNA methylation detection
methods. Discovering molecular correlates is important in
cancer research because it may: 1) provide clues to patho-
genesis; 2) propose or support the existence of a new
molecular subtype; 3) alert investigators to potential con-
founding in association studies; and 4) suggest surrogate
markers in clinical or research settings. We used quantitative
DNAmethylation assays (MethyLight), which are essential to
reproducibly differentiate low-level methylation from high-
level methylation [38]. Compared to high-level methylation,
low-level promoter methylation does not generally silence
gene expression and, thus, can be regarded as biologic
noise [38]. Our resource of a large number of samples of
colorectal cancer (relatively unbiased samples compared to
retrospective or single hospital–based samples), derived
from two large prospective cohorts, has enabled us to
precisely estimate the frequency of colorectal cancers with
specific molecular features (e.g., nuclear b-catenin expres-
sion, CIMP-high, MSI-high, and so on).
In particular, we sought to decipher the relationship
between b-catenin and MSI/CIMP status. Molecular classifi-
cation based on MSI and CIMP statuses is increasingly
important [25] because MSI and CIMP statuses reflect global
genomic and epigenomic aberrations in colorectal cancer
cells. Promoter CpG island methylation in tumor-suppressor
genes has been shown to be an important mechanism in the
development of various human malignancies, including co-
lorectal cancer [1,44–47]. We have demonstrated that nu-
clear and cytoplasmic b-catenin expressions (i.e., b-catenin
activation) are inversely correlated with CIMP-high, indepen-
dent of MSI status. Previous studies have shown an inverse
relationship between b-catenin activation and MSI-high [24–
26]. We have further demonstrated that the inverse relation
between MSI and b-catenin is indirect and is mediated by
CIMP because MSI status is not correlated with b-catenin
expression after stratification by CIMP status. Interestingly,
APC promoter methylation has been shown to be inversely
correlated with features of CIMP in colorectal cancer [15].
Together with our results, it is likely that not only APC
promoter methylation but also overall WNT/b-catenin activa-
tion is inversely correlated with CIMP.
We assessed b-catenin activation status by immunohisto-
chemistry because b-catenin localization reflects the status
of b-catenin activation. Regardless of the mechanism of
b-catenin activation (i.e., a mutation in APC or other mecha-
nisms), b-catenin accumulates in the cytoplasm and nucleus,
then activates the WNTsignaling pathway. Although previous
studies have shown positive correlations between ‘‘CTNNB1
(the b-catenin gene) mutations’’ and MSI-high in colorectal
cancer [22,23], these studies did not examine the frequen-
cies of cytoplasmic or nuclear b-catenin localization (i.e., the
overall frequencies of b-catenin activation). In fact, CTNNB1
mutation constitutes a mechanism of b-catenin/WNT activa-
tion in only a minority of colorectal cancers [19]. Thus, b-
catenin localization is a reasonable surrogate marker when
one evaluates the overall frequency of b-catenin activation.
Interestingly, we have shown that COX-2 overexpres-
sion is correlated positively with cytoplasmic b-catenin ex-
pression, but not significantly with nuclear or membrane
expression. A previous study also did not show a signifi-
cant relationship between COX-2 expression and nuclear
b-catenin [48]. A possible link between COX-2 and the WNT
signaling pathway has been suggested [10]. COX-2 has
been shown to activate b-catenin through prostaglandin E2
and G protein–coupled receptor EP2 [11]. A recent study
has also shown that b-catenin stabilizes COX-2 mRNA by
interacting with AU-rich elements in a 3V untranslated region
[12]. Considering these data, it may be possible that COX-2
and b-catenin may form a positive feedback loop. Our data
support the role of cytoplasmic b-catenin in stabilizing COX-2
(PTGS2) mRNA. That might be the reason why the relation-
ship between COX-2 and b-catenin expression appears to be
limited to cytoplasmic b-catenin.
We have analyzed b-catenin expression in each cellular
compartment (cytoplasm, nucleus, and membrane), and we
have also used the b-catenin scoring system based on the
Figure 5. Frequency of cytoplasmic -catenin expression in colorectal cancer
stratified by p53 and COX-2 statuses.
Figure 4. Frequency of -catenin expression and -catenin scores z 4 in
colorectal cancer stratified by CIMP and COX-2 statuses.
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methods of Jass et al. [26]. We have shown that separately
analyzing cytoplasmic b-catenin expression and nuclear
expression is also valuable because associations might be
limited to expression in only one of the compartments (as
shown by the association between COX-2 and cytoplasmic
b-catenin in this study). Thus, molecular correlates with
b-catenin expression in each compartment (in particular,
cytoplasm and nucleus) can be valuable.
In conclusion, b-catenin activation is inversely associated
with CIMP-high in colorectal cancer independent of MSI or
BRAF status. Cytoplasmic b-catenin localization is correlated
positively with COX-2 overexpression. Our results indicate that
one should examine CIMP status when analyzing the WNT/
b-catenin pathway in relation to clinical and/or other molecular
variables because CIMP status reflects global epigenomic
status in tumor cells and may be a confounding factor. The
exact mechanisms of these molecular correlates in colorectal
cancer need to be elucidated by additional studies.
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